Saving the mind faces high hurdles.
Travis
John
J
D000544:Alzheimer Disease / Q000188:drug therapy*; D023582:Alzheimer Vaccines / Q000627:therapeutic use; D053829:Amyloid Precursor Protein Secretases; D016229:Amyloid beta-Peptides / Q000378:metabolism; D016282:Aspartic Acid Endopeptidases / Q000378:metabolism; D015415:Biomarkers; D001709:Biotechnology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D010450:Endopeptidases; D006801:Humans; D023421:Models, Animal; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D018697:Nootropic Agents / Q000627:therapeutic use*; D010766:Phosphorylation; D011480:Protease Inhibitors / Q000627:therapeutic use; D016875:tau Proteins
D023582:Alzheimer Vaccines; D016229:Amyloid beta-Peptides; D015415:Biomarkers; D002800:Cholinesterase Inhibitors; C054369:MAPT protein, human; D009419:Nerve Tissue Proteins; D018697:Nootropic Agents; D011480:Protease Inhibitors; D016875:tau Proteins; D053829:Amyloid Precursor Protein Secretases; D010450:Endopeptidases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human